Ася Казанцева - В интернете кто-то неправ! Научные исследования спорных вопросов

31 Публикация Роспотребнадзора об инфекционной заболеваемости в РФ: http://rospotrebnadzor.ru/activi-ties/statistical-materials/statictic_details.php?ELEMENT_ ID=2938

32 Интервью с сотрудниками НИИ вакцин и сывороток: http://22century.ru/docs/impfung

1 Соболезнования по поводу смерти Нозифо Бенгу от Treatment Action Campaign: http://www.tac.org.za/community/ node/2210

2 Описание диеты Нозифо: http://www.economist.com/ node/7033269

3 Natrass N. Antiretroviral treatment and the problem of political will in South Africa // Southern African Journal of HIV Medicine , 2006, Vol. 7 (2), 29–31.

4 Chigwedere P. et al. Estimating the lost benefts of an-tiretroviral drug use in South Africa // Journal of Acquired Immune Defciency Syndromes, 2008, Dec. 1; 49 ( 4 ), 410–415.

5 Описание первых случаев оппортунистических инфекций на сайте Центров по контролю и профилактике заболеваний: http://www.cdc.gov/mmwr/preview/mmwrht-ml/lmrk077.htm

6 Barre-Sinoussi F. et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune defcien-cy syndrome (AIDS) // Science , 1983, May 20, Vol. 220(4599), 868–871.

7 Popovic M. et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV–III) from patients with AIDS and pre-AIDS // Science , 1984, May 4, Vol. 224, No. 4648, 497–500.

8 Sarngadharan M. et al. Antibodies reactive with human T-lymphotropic retroviruses (HTLV–III) in the serum of patients with AIDS // Science , 1984, May 4, Vol. 224(4648), 506–508.

9 Gao F. et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes // Nature , 1999, Vol. 397, 436–441.

10 D’arc M. et al. Origin of the HIV-1 group O epidemic in western lowland gorillas // PNAS , 2015, Vol. 112, No. 11, E1343–E1352.

11 Chen Z. et al. Genetic characterization of new West African simian immunodefciency virus SIVsm: geographic clustering of household-derived SIV strains with human immuno-defciency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop // Journal of Virology , June 1996, Vol. 70, No. 6, 3617–3627.

12 Kalish M. et al. Central African hunters exposed to Simian immunodefciency virus // Emerging Infectious Diseases , 2005 Dec., Vol. 11(12), 1928–1930.

13 Gilbert T. et al. The emergence of HIV/AIDS in the Americas and beyond // PNAS , 2007, Vol. 104, No. 47, 18566– 18570.

14 Пиневич А. В., Сироткин А. К., Гаврилова О. В., Потехин А. А. Вирусология : учебник. СПб.: Издательство Санкт-Петербургского университета, 2012. 432 с.

15 Ярилин А. А. Иммунология : учебник. М.: ГЭОТАР-Медиа, 2010. 752 с.

16 Атлас по медицинской микробиологии, вирусологии и иммунологии: Учебное пособие для студентов медицинских вузов / под ред. А. А. Воробьева, А. С. Быкова. М.: Медицинское информационное агентство, 2003. 236 с.

17 Doitsh G. et al. Cell death by pyroptosis drives CD4 T– cell depletion in HIV-1 infection // Nature , Jan. 2014, Vol. 505, 509–514.

18 The Durban Declaration // Nature , July 2000, Vol. 406, 15–16. Доступна по ссылке: http://www.nature.com/nature/journal/ v406/n6791/full/406015a0.html

19 De Clercq, E. The history of antiretrovirals: key discoveries over the past 25 years // Reviews in Medical Virology , Sep. 2009, Vol. 19, Issue 5, 287–299.

20 Volberding P. et al. Zidovudine in asymptomatic human immunodefciency virus infection. A controlled trial in persons with fewer than 50 °CD4-positive cells per cubic millimeter // New England Journal of Medicine , 1990, Vol. 322(14), 941–949.

21 Dournon E. et al. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex // Lancet , Dec. 1988, Vol. 332, No. 8623, 1297–1302.

22 Connor E. et al. Reduction of maternal-infant transmission of human immunodefciency virus type 1 with zidovu-dine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group // New England Journal of Medicine , Nov. 1994, 3; Vol. 331(18), 1173–1180.

23 Larder B, Kemp A. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT) // Science , Dec. 1989: Vol. 246, No. 4934, 1155–1158.

24 Hammer S. et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodefcien-cy virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team // New England Journal of Medicine , 1997, Sep. 11, Vol. 337(11), 725–733.

25 Gulick R. et al. Treatment with Indinavir, Zidovudine, and Lamivudine in adults with human immunodefciency virus infection and prior antiretroviral therapy // New England Journal of Medicine , 1997, Vol. 337, 734–739.

26 Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies // Lancet , 2008, Vol. 372, 293–299.

27 Weller S., Davis K. Condom effectiveness in reducing heterosexual HIV transmission // The Cochrane Database of Systematic Reviews , 2002.

28 Townsend C. et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011 // AIDS, Apr. 2014, Vol. 28, Issue 7, 1049–1057.

29 Коалиция по готовности к лечению. Закупки АРВ-препаратов в 2014 году: хроника децентрализации. Результаты мониторинга закупок и предоставления АРВ-препаратов в РФ. Санкт-Петербург, 2015. Публикация доступна на сайте http://itpcru.org

30 Hutter G. et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation // New England Journal of Medicine, Feb. 2009, Vol. 360, 692–698.

31 Hutter G., Thiel E. Allogeneic transplantation of CCR5-defcient progenitor cells in a patient with HIV infection: An update after 3 years and the search for patient no. 2 // AIDS, Jan. 2011, Vol. 25, Issue 2, 273–274.

32 Yukl S. et al. Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient // PLOS Pathogens, May 2013, Vol. 9(5), e1003347.

33 Brown T. I am the Berlin patient: A personal refection // AIDS Research and Human Retroviruses, Jan. 2015, Vol. 31, No. 1, 2–3.

34 Poropatich K., Sullivan D. Human immunodefciency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression // Journal of General Virology, February 2011, Vol. 92, No. 2, 247–268.

35 Saez-Cirion A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study // PLOS Pathogens, Mar. 2013, Vol. 9(3), e1003211.

36 Lehrman G., Hogue I. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study // Lancet, Aug. 2005, Vol. 366(9485), 549–555.